|Tested species reactivity||Horse, Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2b, kappa|
|Immunogen||A431 human epidermoid cells|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunofluorescence (IF)||Assay Dependent|
|Immunohistochemistry (Frozen) (IHC (F))||Assay Dependent|
|Immunoprecipitation (IP)||2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13045 targets Epidermal Growth Factor Receptor in FACS, IF, IHC (F), and IP applications and shows reactivity with Equine and Human samples.
The MA5-13045 immunogen is a431 human epidermoid cells.
The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. Multiple alternatively spliced transcript variants that encode different protein isoforms have been found for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer.
MA5-13045 was used in immunoprecipitation to study tumor penetration and EGFR saturation by panitumumab and the correlation with therapeutic efficacy in a xenograft model of human epidermoid carcinoma
|Freeman DJ,McDorman K,Ogbagabriel S,Kozlosky C,Yang BB,Doshi S,Perez-Ruxio JJ,Fanslow W,Starnes C,Radinsky R||Molecular cancer (11:null)||2012|
Optical nanomanipulations of malignant cells: controlled cell damage and fusion.
MA5-13045 was used in blocking or activating experiment to study optical nanomanipulations of malignant cells
|Minai L,Yeheskely-Hayon D,Golan L,Bisker G,Dann EJ,Yelin D||Small (Weinheim an der Bergstrasse, Germany) (8:1732)||2012|
Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling.
MA5-13045 was used in blocking or activating experiment to study ligand-independent dimer formation of epidermal growth factor receptor
|Yu X,Sharma KD,Takahashi T,Iwamoto R,Mekada E||Molecular biology of the cell (13:2547)||2002|
A chimeric pre-ubiquitinated EGF receptor is constitutively endocytosed in a clathrin-dependent, but kinase-independent manner.
MA5-13045 was used in immunocytochemistry and immunohistochemistry to study the roles of EGFR kinase activity and ubiquitination in EGFR endocytosis
|Bertelsen V,Sak MM,Breen K,Rødland MS,Johannessen LE,Traub LM,Stang E,Madshus IH||Traffic (Copenhagen, Denmark) (12:507)||2011|
The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2.
MA5-13045 was used in immunocytochemistry to investigate the effect of the constitutive activity of EGFRvIII on wild-type EGFR and erbB2 in OVCA 433 cells
|Zeineldin R,Ning Y,Hudson LG||The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (58:529)||2010|
Effects of cisplatin, alpha-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines.
MA5-13045 was used in immunocytochemistry to investigate the effects of chemotherapeutic agents cisplatin, alpha-interferon, and 12-cis retinoic acid on the expression of mutliple proteins in oral cancer cell lines
|Sundelin K,Roberg K,Grénman R,Håkansson L||Journal of oral pathology and medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (36:177)||2007|
Both clathrin-positive and -negative coats are involved in endosomal sorting of the EGF receptor.
MA5-13045 was used in immunocytochemistry to study the endosomal sorting of EGFR and the role played by clathrin-positive and clathrin-negative coats
|Myromslien FD,Grøvdal LM,Raiborg C,Stenmark H,Madshus IH,Stang E||Experimental cell research (312:3036)||2006|
Activation of the epidermal growth factor (EGF) receptor induces formation of EGF receptor- and Grb2-containing clathrin-coated pits.
MA5-13045 was used in immunocytochemistry to study clathrin-coated pits containing EGF, EGFR and Grb2 and the role of EGFR activation in their formation
|Johannessen LE,Pedersen NM,Pedersen KW,Madshus IH,Stang E||Molecular and cellular biology (26:389)||2006|
The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane.
MA5-13045 was used in immunocytochemistry to study the inhibitory effect of ErbB2 on EGF-induced formation of clathrin-coated pits
|Haslekås C,Breen K,Pedersen KW,Johannessen LE,Stang E,Madshus IH||Molecular biology of the cell (16:5832)||2005|
Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines.
MA5-13045 was used in immunocytochemistry to investigate the patterns of colony formation in cell lines derived from carcinomas
|Locke M,Heywood M,Fawell S,Mackenzie IC||Cancer research (65:8944)||2005|
Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.
MA5-13045 was used in immunocytochemistry to study the role of Akt phosphorylation in the inhibition of ErbB2 signaling by Herceptin
|Longva KE,Pedersen NM,Haslekås C,Stang E,Madshus IH||International journal of cancer (116:359)||2005|
Ultrastructural characterization of giant endosomes induced by GTPase-deficient Rab5.
MA5-13045 was used in flow cytometry to study the ultrastructure of giant endosomes induced by GTPase-deficient Rab5
|Wegner CS,Wegener CS,Malerød L,Pedersen NM,Progida C,Prodiga C,Bakke O,Stenmark H,Brech A||Histochemistry and cell biology (133:41)||2010|
The juxtamembrane region of the EGF receptor functions as an activation domain.
MA5-13045 was used in flow cytometry to study the role of the juxtamembrane region of the EGF receptor as an activation domain
|Red Brewer M,Choi SH,Alvarado D,Moravcevic K,Pozzi A,Lemmon MA,Carpenter G||Molecular cell (34:641)||2009|
Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
MA5-13045 was used in flow cytometry to study the interplay among epidermal growth factor receptor, ErbB2, and ErbB3 during the treatment of breast cancer and its therapeutic significance
|Pedersen NM,Breen K,Rødland MS,Haslekås C,Stang E,Madshus IH||Molecular cancer research : MCR (7:275)||2009|
Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane.
MA5-13045 was used in flow cytometry to study the regulation of EGF receptor signaling by plasma membrane erbB2
|Offterdinger M,Bastiaens PI||Traffic (Copenhagen, Denmark) (9:147)||2008|
Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.
MA5-13045 was used in immunohistochemistry to investigate the sub-classification invasive breast carcinoma patients and its prognostic significance
|Goldstein NS,Decker D,Severson D,Schell S,Vicini F,Margolis J,Dekhne NS||Cancer (110:1687)||2007|
Abnormal beta-catenin expression in oral cancer with no gene mutation: correlation with expression of cyclin D1 and epidermal growth factor receptor, Ki-67 labeling index, and clinicopathological features.
MA5-13045 was used in immunohistochemistry to study beta-catenin expression in oral cancer
|Odajima T,Sasaki Y,Tanaka N,Kato-Mori Y,Asanuma H,Ikeda T,Satoh M,Hiratsuka H,Tokino T,Sawada N||Human pathology (36:234)||2005|
Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.
MA5-13045 was used in immunohistochemistry to study the prognostic value of nuclear-localized EGFR in beast cancer
|Lo HW,Xia W,Wei Y,Ali-Seyed M,Huang SF,Hung MC||Cancer research (65:338)||2005|
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
MA5-13045 was used in immunohistochemistry to study the expression of HER1-4 in 220 cases of breast carcinoma and the correlation with survival
|Witton CJ,Reeves JR,Going JJ,Cooke TG,Bartlett JM||The Journal of pathology (200:290)||2003|
Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis.
MA5-13045 was used in immunohistochemistry to investigate the incidence of EGFRvIII in human invasive breast cancer
|Ge H,Gong X,Tang CK||International journal of cancer (98:357)||2002|